EyePoint Pharmaceuticals


Victor Liu


Mr. Liu has over 20 years of experience in the pharmaceutical industry. Since November 2018, he has served as executive director and Chief Executive Officer of OcuMension Therapeutics (a company listed on Hong Kong Stock Exchange, stock code:1477), a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies.

Prior to joining OcuMension Therapeutics, he served as the chairman and general manager in Santen Pharmaceutical (China) Co., Ltd. (参天制药(中国)有限公司) from October 2014 to July 2018. From February 2009 to September 2014, Mr. Liu served as the head of pharmaceutical affair division and later became the general manager of Eisai (China) Inc. (卫材(中国)药业有限公司), responsible for the management of pharmaceutical affairs and development, and the overall corporate operation, respectively. From October 2006 to February 2009, Mr. Liu held positions including the national sales, senior business development manager, and the head of sales in Sandoz China Pharmaceutical Co., Ltd. (山德士(中国)制药有限公司), responsible for marketing, sales and business development.

EyePoint Pharmaceuticals